Q-omics provides the consensus-scored LRRC71 profile across patient tissues and cancer cell-line models. LRRC71 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, LRRC71 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, LRRC71 RNA expression shows 15,968 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, KIRC, and UVM as cancer lineages where LRRC71 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRRC71 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRRC71 survival associations across molecular data types. LRRC71 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRRC71 RNA expression–survival associations across cancer types. High LRRC71 expression shows unfavorable associations in ACC, MESO, KIRC, CESC, READ and LGG. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for LRRC71 RNA expression.
This table summarizes LRRC71 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for LRRC71. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRRC71 shows lower tumor expression in LUAD, LUSC, KICH and THCA and higher tumor expression in KIRC and LIHC. The KIRC box plot shows higher LRRC71 RNA expression in tumor versus normal tissue (log2 FC = +0.205, t-test p < 0.001).
This table shows molecular features associated with LRRC71 in patient tissues and cancer cell lines. In patient samples, LRRC71 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, LRRC71 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LIVER and URINARY_TRACT.
